Correction to Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials

Documenti analoghi

• Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials
  di: Matthew P. Kosloski, et al.
  Pubblicazione: (2024)
• Pharmacokinetics and pharmacodynamics of mibavademab (a leptin receptor agonist): Results from a first‐in‐human phase I study
  di: Andrew Gewitz, et al.
  Pubblicazione: (2024)
• Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose‐escalation phase I study
  di: Jia‐yu Zhang, et al.
  Pubblicazione: (2024)
• T cell immunophenotypes and IgE responses in patients with moderate‐to‐severe atopic dermatitis receiving dupilumab
  di: Davender Redhu, et al.
  Pubblicazione: (2025)
• Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data
  di: Huijun Chen, et al.
  Pubblicazione: (2024)